Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

Johnson & Johnson reported revenue of $25 billion for the quarter, up 6%, and raised its full-year guidance to $101.1 billion. The beat was powered by Darzalex, which climbed 18%, and Tremfya, which surged 72%, offsetting declines in Stelara as the drug faces biosimilar competition.

The stock has rallied 22% year-to-date and now trades near valuation peaks, a headwind for new entries at current levels. JNJ maintains a portfolio of more than 28 blockbuster products and has raised its dividend for over 50 consecutive years, reinforcing its appeal to income-focused accounts.

The guidance raise signals management confidence in the drug pipeline's momentum, particularly in immunology and oncology franchises. With Darzalex and Tremfya posting double-digit growth, JNJ is demonstrating pricing power and market-share gains in high-margin categories despite patent-cliff pressures elsewhere in the portfolio.